A Randomized, Double-Blind, Placebo-Controlled, Phase-2B Study to Assess the Safety and Efficacy Effects of ART-123 on Subjects With Sepsis and Disseminated Intravascular Coagulation.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase-2B Study to Assess the Safety and Efficacy Effects of ART-123 on Subjects With Sepsis and Disseminated Intravascular Coagulation.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Nov 2016

At a glance

  • Drugs Thrombomodulin alfa (Primary)
  • Indications Disseminated intravascular coagulation; Sepsis
  • Focus Therapeutic Use
  • Sponsors Asahi Kasei Pharma America Corp
  • Most Recent Events

    • 01 Sep 2013 Results published in Critical Care Medicine.
    • 10 Dec 2012 Results presented at the 54th Annual Meeting and Exposition of the American Society of Hematology.
    • 30 May 2012 Inclusion and exclusion criteria amended as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top